• Clinical study HYPER-H21-1 evaluates the use of patented DehydraTECH(TM)-processed CBD for use against hypertension
• Hypertension is a primary or contributing factor in the death of almost 500,000 people per year, with approximately one in four adults aged 20 to 44 suffering from high blood pressure
• Initial results of the study show that blood pressure was reduced in both male and female volunteers, resulting in the reinforcement of pre-existing findings demonstrating that DehydraTECH delivers superior performance
• Lexaria plans on launching two additional clinical trials, for a total of three clinical trials in 2021 for the DehydraTECH-CBD with hypertension applications

Lexaria (NASDAQ: LEXX), a global innovator of proprietary patented drug delivery platform DehydraTECH(TM), has released partial results from human clinical study HYPER-H21-1. The study evaluates DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension (https://ibn.fm/4hiM1). Hypertension, also referred to as high blood pressure, is a primary or contributing factor in the deaths of almost 500,000 people per year. Hypertension can double the risk of having a heart attack or quadruple the chance of having a stroke. The likelihood of heart failure, vision loss, renal disease, peripheral artery disease, dementia, and more can be attributed to cases of high blood pressure. Statistically, one in four adults aged 20 to 44 has high blood pressure. The partial results showed that blood pressure was reduced across both male and female volunteers; it was most pronounced with DehydraTECH-CBD in the study’s first 10 to 50 minutes. These results reinforced the pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic CBD controls. Chris Bunka, CEO of Lexaria, commented on the study, saying, “We are very encouraged by these early results in our 2021 hypertension program. Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in Stage 2 hypertensive volunteers.” Lexaria’s DehydraTECH technology is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. The method increases the effectiveness and improves the way that active pharmaceutical ingredients enter the bloodstream (like CBD). Benefits of the delivery method include:

• Quicker delivery
• Increase in bioavailability
• Increase in the brain absorption
• Improved drug potency
• Reduced drug administration cost
• Masked unwanted taste

Lexaria has demonstrated these benefits from other animal studies, elevating the quantity of the drug delivered across the blood-brain barrier by as much as 1,900%. Lexaria was also pleased that the subjects of this human clinical study tolerated the DehydraTECH-CBD, with no serious adverse events or side effects observed or reported. The concentration-matched, generic CBD control ingested resulted in unwanted side effects in some volunteers — primarily gastrointestinal problems, including diarrhea. Lexaria plans to complete its ongoing additional sample and data analyses work for this study, reporting upon those outcomes when complete. A second human clinical hypertension study, HYPER-H21-2, has completed dosing, with three different doses of DehydraTECH-CBD (150mg per dose), administered evenly over the course of a 24-hour monitoring period. The company is optimistic that repeated dosing over this sustained period may further enhance efficacy. The results of both studies will be evaluated and considered before the company begins its planned third human clinical hypertension study planned for fall 2021. Lexaria is considering evaluations for a fourth, expanded, randomized, controlled human clinical hypertension trial. The fourth trial will be dependent on the results from the current trials and investigations into a larger population for a more enhanced statistical and clinical significance. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• PlantX Life is becoming a one-stop shop solution for fans of plant-based foods and other products
• The company has expanded its plant-based meal delivery service in Canada and has launched a similar food-delivery service across Southern California
• PlantX Life also recently announced year-end financials after nearly a year-and-a-half since its incorporation, showing gross revenue of $6.58 million as of March 31
• To help the company meet strategic growth goals, PlantX Life has restructured its administration, naming former CFO Lorne Rapkin as the new CEO and former CEO Julia Frank as the new COO

A British Columbia, Canada-based company with the potential to become an Amazon-like retailer for the plant-sustained community is reporting its continued growth in the United States and in its revenue stream. PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) recently noted the launch of its XFood plant-based meal delivery service in the United States, as well as its year-end financial results and a restructuring of its leadership. PlantX Life’s platform presents itself as the one-stop shop for everything plant-based, with more than 5,000 plant-based products and plans to expand its product lines from meal and indoor plant deliveries to cosmetics, clothing and its own water brand via e-commerce and brick-and-mortar stores. PlantX has stated its flagship physical store locations will be in Squamish, British Columbia; San Diego, California; and Tel Aviv in the state of Israel (https://ibn.fm/VG8AV). The company announced July 28 that it is launching its XFood delivery service in Southern California, utilizing a ghost kitchen in central Los Angeles as part of an operation similar to food delivery services it is offering in Canada. The company’s San Diego store will open in September and PlantX expects to eventually expand its food delivery services across the United States. “It has long been a dream of ours to be able to deliver food outside of the restaurant setting and in a more personal and personalized way,” PlantX Chief Culinary Officer Matthew Kenney stated in the news release (https://ibn.fm/x3gx9). Kenney added that the three-day meal kits for vegan recipes he has designed and curated “are a representation of how we can build a future where healthy, high-quality food is available to everyone on a daily basis” and that his team’s weekly meal plans reflect the “utmost in health, purity, and of course, pleasure.” PlantX reported July 30 that its year-end (“YE”) financial outlook shows gross revenue of $6.58 million as of March 31, compared with $1,349 for the previous YE statement that reflected the company’s first five months since its Oct. 11, 2019 incorporation, with a gross margin of 21 percent (https://ibn.fm/9Eac6). Its Q4 gross revenue grew 134 percent over Q3, according to the report, with a gross margin of 23 percent in Q4 compared with 20 percent in Q3. “PlantX has been growing its revenue each quarter. We are attributing this to the Company’s investments in operational activities designed to strategically support PlantX’s growth plan,” company founder Sean Dollinger stated as part of the news release. “We are thoroughly focused on six key pillars to ensure the success of our growth strategy: marketing activities, boosting product and service diversity, supply chain expansion, geographic expansion and completing strategic acquisitions.” In order to continue advancing the company toward fulfillment of its goals, PlantX announced Aug. 4 that it is restructuring its administrative operations, with former CEO Julia Frank becoming the chief operating officer and former CFO Lorne Rapkin taking over her place as CEO. Director of Finance Shariq Khan will succeed Rapkin as the new CFO (https://ibn.fm/Uv6uQ). Other corporate news includes the announcements that PlantX has completed its integration as a seller on Walmart Canada Marketplace and Hudson’s Bay Marketplace, that cold-pressed juices maker Little West, LLC, has completed its integration as a subsidiary in the company’s operational structures, and that Khan has been granted 50,000 restricted share units for the term of a year. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• SRAX updates Sequire investor analytics platform with Investment Advisor Feature that allows users to find investment advisor contact information
• Replays from the 2021 Sequire Blockchain Conference now available on demand for next three months
• Blockchain Conference featured 10+ leading blockchain and cryptocurrency companies, keynote presentations from industry experts

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, just upgraded the user experience with a new Investment Advisor Feature (https://ibn.fm/SM6Pr) and on-demand presentation replays from the Sequire Blockchain Conference (https://ibn.fm/blbPW). “This conference was one of the best we’ve ever put on. The content was educational and the companies that presented are paving the way for a crypto future,” said SRAX CEO and Founder Christopher Miglino. “If you have not already watched the presentations and want to be educated on what companies are doing in the space, I would encourage you to view these amazing panels and presentations.” Along with company presentations, the conference featured keynotes by prominent thought leaders and industry royalty, including Brock Pierce, Maja Vujinovic, Saum Noursalehi, Rachel Wolfson, George Stella, Brittany Kaiser, Gilbert Hill Justin Newton, Adrian Baschuk, Bryan Bullett, Fred Thiel and Ibrahim AlHusseini. SRAX has made all the company replays and exclusive keynotes available for the next three months. The panels include topics such as stable coin viability, innovations in mining, industry sustainability, and data privacy. The conference was hosted on Sequire, SRAX’s investor analytics platform. With its unique suite of tools, Sequire helps public companies unlock the power of investor trading insights with metrics that include trading data, current share price, volume change, % change, and more. As the popularity of Sequire continues to soar, SRAX keeps adding new features – such as the recently released Investment Advisor Feature that provides contact information and filtering capabilities that enable users to create groups for targeted communications. “Registered Investment Advisors have been the largest investors in our company SRAX and have been a significant part of the growth of our shareholder base. We are now providing the tools that will enable issuers to identify, communicate with and track the progress of specific advisors,” said Miglino. “Issuers can use this new feature to organize in-person events in specific geographic areas or launch virtual events on the Sequire Audience platform. Once you identify the prospective candidates, the Sequire CRM can help track the progress with a specific advisor.” Since its creation in 2019, Sequire has grown to over five million active retail investors across 180+ companies (https://ibn.fm/VWnIU). With its unique suite of tools, Sequire helps companies track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. To view the presentations and keynotes from the 2021 Sequire Blockchain Conference visit https://blockchain21.mysequire.com. For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• InnerScope officially “Pink Current” after filing reports with OTC Markets
• Company CEO and President Matthew Moore will be presenting at SNN Network Summer Virtual Event 2021 on Wednesday, Aug. 18 at 3:00 p.m.
• Company’s DTC hearing aid demand expected to grow following Biden Executive Order directed at market liberalization

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer (“DTC”) hearing technology space, will be presenting at the SNN Network Summer Virtual Event at 3:00 p.m. on Wednesday, Aug. 18, 2021. In addition to hosting the event, InnerScope Hearing Technologies CEO and President Matthew Moore will answer investor questions on various topics, including the upcoming deregulation of the hearing aid market (https://ibn.fm/fyadn). The company, now officially “Pink Current” after filing reports with OTC Markets (https://ibn.fm/a7iec), will be providing critical information about its recently released direct-to-consumer hearing aid products currently available at the company’s online store. Demand for InnerScope’s OTC hearing aid products is expected to increase sharply as a result of President Biden’s sweeping executive order that directs the U.S. Department of Health and Human Services “to consider issuing proposed rules within 120 days for allowing hearing aids to be sold over the counter” (https://ibn.fm/Zbg4D). “InnerScope is very pleased to announce today that we are again current with our financial reporting,” said Moore. “We also plan to upgrade our security to the OTCQB once we meet the independent director and other requirements and hope to announce this in the near term. Both of these steps are expected to increase shareholder value and, once these items are in our rearview mirror, allow us to continue focusing on driving market penetration and revenue expansion for InnerScope’s innovative and affordable direct-to-consumer hearing products.” In anticipation of the increased over-the-counter (“OTC”) demand for hearing aids, InnerScope launched a six-month national “Media Blitz” campaign aimed at an estimated 48 million Americans currently suffering from hearing loss (https://ibn.fm/LuBmy). Along with a minimum of 660 commercials and 156 digital billboards running throughout lower Manhattan in New York City, the campaign will also include spots on major networks that include Fox News, Bloomberg, Fox Business Network, CNN, CNBC, Newsmax TV, and MSNBC. “The launch of our Hearing Loss Media Blitz Campaign could not have come at a better time, especially after last week’s executive order from President Biden,” said Moore. “InnerScope’s hearing aids work with any smartphone, require no medical evaluation or professional help, and deliver the same personalized hearing quality and satisfaction as hearing aids sold by hearing care professionals.” Doctor-prescribed hearing aids can cost up to $6,000 for each device, putting them out of reach for millions of hearing-impaired people throughout the world (https://ibn.fm/Fh0Yg). As a result, InnerScope is ideally positioned to capture significant market share of the OTC market with direct-to-consumer sales of its Bluetooth-powered self-adjusting rechargeable hearing aids, doctor-formulated health supplements and other hearing-related products at its dedicated online store. To register for the SNN Network Summer Virtual Event, please visit https://conference.snn.network/signup. To learn more about InnerScope Hearing Technologies, please visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• U.S. government infrastructure plans, rising housing demand, seasonal trends pointing to potential 65% increase in lumber prices by end of 2021
• SGTM transforms storm waste into gardening mulch, playground surfacing material, specialty cypress lumber
• Clients include Circle K, The Kroger Company, 7-Eleven, Old Castle Lawn & Garden
• Company completed two-year audit, commenced FORM-10 process in preparation for NASDAQ uplist

Biden’s infrastructure plans, seasonal trends and an expected increase in housing demand are setting the stage for a potential 65% increase in the cost of lumber, according to experts (https://ibn.fm/K3vD5). Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, is positioned to benefit from rising prices through the manufacture of specialty cypress lumber via the company’s sawmill operations. Lumber prices may have taken a fall from their 2020 peak, but analysts are expecting a sharp rebound by the end of 2021. The nearly $1 trillion bipartisan infrastructure deal, combined with the continued rise of housing prices and seasonal trends, is setting the stage for a massive increase in the cost of lumber according to Joshua Mahony, a senior market analyst at the IG trading platform (https://ibn.fm/K3vD5). “There is good reasoning behind the idea that the losses we are seeing over recent months could soon enough bring another major buying opportunity for the bulls to come back into dominance,” said Mahony. “That reversal historically results in a bullish reversal to regain lost ground and bring us back into a positive end to the year. This current pullback is in fact part of a seasonal trend that typically resolves in a dramatic recovery towards the end of the year.” SGTM is poised to benefit from the lumber price rally by providing synergistic and environmentally beneficial solutions to tree and storm waste disposal that have historically created environmental burdens on disposal sites around the country. Rather than allow this natural waste to be directed to landfills, SGTM collects tree biomass and transforms it into playground surfacing material, specialty cypress lumber, and a variety of organic, next-generation mulch products that allow water and air to penetrate the soil and roots — a vital process that promotes plant health and growth. After concluding a record-breaking year in 2020 with impressive financial results so far in 2021, SGTM continues its expansion plans through a strategy that focuses on organic growth, relationships with strategic partners, and expanded relationships with top global franchises that include Circle K, The Kroger Company, 7-Eleven and Old Castle Lawn & Garden. In addition to completing a two-year audit, the company commenced its FORM-10 process to become fully reporting with future plans to uplist to NASDAQ. SGTM’s centralized operations are based in Jacksonville, Florida across 26 acres with ample room to expand. With over 40 years of next-level experience with mulch manufacturing and tree management, SGTM’s leadership is committed to sustainably growing the company through a multi-pronged strategy that puts stewardship of the environment at the core of its mission. To learn more about Sustainable Green Team, please visit www.NationalArborCare.com and view the investor presentation at https://ibn.fm/GBgnK. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Research shows one in three cannabis users drink less alcohol when compared to before legalization, 84% feel cannabis is safer, nearly half (47%) prefer cannabis over alcohol
• BevCanna specializes in the production of in-house and white-label cannabis-infused beverages using Canadian premium alkaline spring water
• BevCanna’s HACCP-certified, 40,000 square foot manufacturing facility operating by GMP standards, current capacity at 210 million bottles per annum
• Extensive retail network spans 3,000+ points of distribution throughout North America

Cannabis-infused beverages are increasing in popularity as the drink of choice for consumers in social settings — a trend that some analysts believe threatens the alcoholic beverage industry (https://ibn.fm/wS24C). BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products company, is positioned to take a sizeable share of the growing market through its focus on quality ingredients, iconic branding, and a retail strategy that leverages over 3,000 points of distribution across North America. Cannabis-infused beverages have rapidly grown in popularity, likely due to their water-soluble nature that allows cannabinoids to absorb quickly into the bloodstream and produce euphoric effects. According to a research report by ICR Strategic Communications and Spectacle, the general use of cannabis and cannabis-infused products has resulted in decreased alcohol use among surveyed participants. According to the research, one in three users report drinking less alcohol than before cannabis legalization, 84% of respondents feel that cannabis is safer than alcohol, and that nearly half (47%) prefer the effects of cannabis over alcohol (https://ibn.fm/ZxIbp). “With market reports and surveys showing that more consumers are seeking alternatives to alcoholic beverages for health and wellness reasons, the rapidly evolving cannabis beverage category is a real game changer,” said Ben Larson, founding board member of the Cannabis Beverage Association (https://ibn.fm/a2HX2). “These drinks can be stimulating, and thanks to cutting-edge technology, taste great and have a quick onset time with precise dosage so one can predict and control the desired effect, similar to knowing how you’ll feel after one glass of wine or beer.” Larson is also the CEO of Vertosa, a preferred cannabis emulsion partner of BevCanna. Vertosa will be the emulsion in BevCanna’s Keef beverages, which it plans to launch across Canada (https://ibn.fm/xTsVY). BevCanna specializes in the production of both in-house and white-label cannabis-infused beverages using premium alkaline spring water bottled at the company’s facility in British Columbia, Canada. With a current capacity of 210 million bottles per annum, the company’s 40,000 square foot beverage and supplement manufacturing facility is HACCP-certified and built to GMP standards with pre-approval by the Agricultural Land Commission to expand the facility to 170,000 square feet. BevCanna’s vision is to be a global leader in health and wellness. The company’s extensive retail network spans 3,000+ points of distribution throughout North America and includes its market-leading TRACE alkaline and mineralized water brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with Keef Brands – the #1 cannabis beverage company in the United States. For more information on BevCanna, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Red White & Bloom released its Q4 2020 and FY 2020 results and later reported its Q1 2021 results
• In its Q4 2020 results, the company posted a 158% quarter-over-quarter increase in revenue from $CA6.1 million in Q3 2020 to $15.7 million
• Its FY revenue grew from nil in 2019 to CA$23.3 million in 2020, while its gross profit was CA$13.35 million in 2020 from nil in 2019
• RWB reported $32.7 million in Q1 2021 adjusted sales, an increase of 14.5% over Q4 2020

In a statement contained in the company’s December 2020 investor deck presentation, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) CEO Brad Rogers observed that multiple deals, “judiciously purchased and diligently structured,” were all coming together to create “the most exciting times in the history of the company.” He further noted that the company was looking to build on its key assets focusing on growing the bottom line for its shareholders (https://ibn.fm/yqIO2). Red White & Bloom recently made two announcements that show its progress thus far and perhaps tell of the dawn of the exciting times. On July 22, the company announced its Q4 2020 and full-year results (https://ibn.fm/ikseA). RWB reported a 158% quarter-over-quarter increase in revenue from CA$6.1 million in Q3 2020 to CA$15.7 million in Q4 2020. The company attributes this increase to the impact of the acquisition the Platinum Premium Cannabis Products (“PV”) on its balance sheet, given that Q4 2020 was the first full quarter post-closing. RWB’s revenue for the year ended December 31, 2020, grew to CA$23.3 million from nil in 2019, while its gross profit for the FY 2020 was CA$13.35 million, or 57% of the FY revenue, compared to nil in 2019. Red White & Bloom closed FY 2020 having made significant strides as it seeks to be the superior and most recognizable cannabis company in the United States. It completed two transformative acquisitions: PV, which is licensed in California and has products being sold in Oklahoma and Michigan, and Mid-American Growers (“MAG”), a company that owns a 3.6-million-square-foot, state-of-the-art technology and science facility that will enable RWB to attain premium value for the products it wishes to cultivate. The company has also raised more than US$110 million since January 1, 2020, which it expects will support its expansion and operations. Additionally, as of July 2, 2021, it had about CA$41 million cash on hand. The company reports adjusted sales for the 1st quarter of $32.7 million, a sequential increase of 14.5% from the prior quarter’s adjusted sales of $28.6 million in Q4 2020. The increase was reduced by the strengthening Canadian dollar and would have been about $1 million higher using a constant dollar comparison (https://ibn.fm/KVHvC). “This was another great quarter for the company as we continued to see strong traction for our brands,” said Brad. “We are building on that momentum and working towards finalizing our revised asset purchase of our Michigan investee to bring their revenue, as well as adjusted sales into IFRS revenue format before the end of this current quarter.” Once this is complete and the expansion of its Florida operations starts bearing fruits, the company expects to finally report in its quarterly results the strength of its accomplishments so far. As such, more is still to come for Vancouver-based Red White & Bloom as it positions itself to be one of the top three multi-state operators in the United States in cannabis and hemp-derived product lines. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• Flora Growth Corp. is a Colombian cannabis cultivator that is building a global cannabis CPG portfolio of premium brands and products
• Flora Growth recently announced an LOI designed to grant it an in-road to Australia’s over-the-counter medical cannabis and CBD commercial markets
• The company also signed an LOI to distribute popular Canadian pain topical brand KaLaya throughout Latin American countries, with exports planned to the United States, and to infuse its established line of products with CBD
• Market analysts predict Australia’s medial cannabis market will explode from about $150 million this year to more than a billion dollars by 2025

The Colombia-based operations of cannabis cultivator, global brand builder and product distributor Flora Growth (NASDAQ: FLGC) are receiving increased attention from market watchers, particularly in the wake of the company’s announcement that it executed a letter of intent (“LOI”) with Australia’s Evergreen Pharmacare Pty Ltd. to supply medical-grade dried flower and derivative cannabis products to Australians through Evergreen’s pharmacy distribution network. A July 27 statement issued by Flora Growth indicated Evergreen helps patients and healthcare practitioners, primarily physicians and pharmacists, obtain medical cannabis products and provides them with additional cannabis-related education about its use, authorization and regulation. Flora Growth will begin shipping its medical-grade cannabis products as soon as it harvests its first commercial crop and secures the necessary export licenses (https://ibn.fm/pkkht). Market analysts at FreshLeaf Analytics (https://ibn.fm/5v5ce) and Prohibition Partners (https://ibn.fm/gGdZy) predict the medical cannabis segment will range in value from about US$150 million this year to up to US$1.5 billion by 2025, and the LOI between Flora Growth and Evergreen positions the Colombian grower (with headquarters in Miami, Florida) at the leading edge of a burgeoning market. “This agreement also provides significant potential upside by allowing us to work with Australian regulators directly and bring our premium brands and established product formulations to the over-the-counter CBD market,” Chief Revenue Officer Jason Warnock stated in the company’s news release, adding that Australian regulators’ recent decision to down-schedule cannabidiol (“CBD”) to a level where it can be sold as an over-the-counter product opens the door to Flora’s strategy for “providing proven cannabinoid wellness and beauty products to consumers around the world.” Flora Growth also recently announced that it has signed an LOI to form a joint venture with Canadian-based Avaria Inc., which manufactures pain cream under its flagship brand KaLaya. KaLaya is distributed nationwide across Canada and anticipates distribution across Latin American countries under the JV, with exports to the United States as Flora Growth manages registration, sales and distribution needs. The upside here is not only bringing these well-received products to international markets, but to also infuse these products with cannabinoids, particularly CBD, in order to generate incremental revenue. Avaria does not currently hold a license in Canada to produce cannabis derived versions of its products at a commercial scale, so the partnership would see Flora Growth’s lab division providing it with a necessary boost to expand its market reach as it supplies the cannabis derivative products and low-cost manufacturing locally in Colombia. In Canada, KaLaya has been recognized as the most popular topical analgesic brand distributed through Canadian retailer Purity Life and by The Shopping Channel in 2020, weighing in as Canada’s fastest growing topical decongestants and analgesics brand, according to Nielsen Market Track. “Given CBD’s association with wellness, KaLaya’s established formulation, and Flora Growth’s low-cost high-quality cannabis, this is a natural partnership we are excited to bring globally,” Flora Growth President and CEO Luis Merchan stated in the news release. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• American Academy of Neurology warns of critical neurologist shortfall amid increased incidence of brain disorders
• Brain Scientific addresses issue with portable, cost-effective brain diagnostic solutions that record EEGs in nearly any setting
• Product development includes creation of AI and ML algorithms to detect seizures, dementia and other brain-related conditions
• NeuroCap and NeuroEEG device patents approved in U.S., Europe and China

With a goal of addressing the current acute neurologist shortfall in the United States (https://ibn.fm/DrxvC), Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, has developed cost-effective and portable proprietary medical devices that are positioned to disrupt the electroencephalogram (“EEG”) market. According to a report from the American Academy of Neurology 2019 Transforming Leaders Program, nearly every U.S. state is experiencing a neurologist shortfall amid an increase in neurological disorders (https://ibn.fm/DrxvC). Experts warn that access to high-level care and diagnosis is immediately required to reduce mental disability, improve patient outcomes and increase the wellbeing of the current pool of neurologists facing quality of life issues. As part of the effort to address the shortfall, Brain Scientific aims to support the industry with the introduction of cost-effective, disposable brain diagnostic solutions that include the NeuroCap(TM) and NeuroEEG(TM). These portable devices are part of the company’s expanded vision for neurology telemedicine, allowing practitioners to collect diagnostic information quickly, upload it to cloud-based infrastructure, and leverage artificial intelligence (“AI”) and machine learning (“ML”) algorithms to detect seizures, dementia and other brain-related conditions. Brain Scientific’s go-to-market strategy emphasizes relationships with leading hospitals, in addition to prioritizing the creation of partnerships with industry leaders in EEG manufacturing and distribution. With an aim to further increase market penetration, the company endeavors to integrate its EEG solution with existing telemedicine platforms to serve the direct neurology market in addition to bundling its diagnostic solutions with products in related sectors to service complimentary markets. The first phase of the company’s three-stage development process was completed in 2019 with the creation of the NeuroCap and NeuroEEG devices. Currently in its second development phase, Brain Scientific is now focused on the creation of secure cloud-based infrastructure to transmit data between neurologists and patients. The final phase, scheduled for late 2021 and 2022, will focus on the development of AI and ML functionality to provide predictive analytics that increases the diagnostic capabilities offered by its devices. Brain Scientific’s NeuroCap and NeuroEEG devices can be used to record EEGs in settings of all types such as neurology clinics, remote clinical research labs, emergency departments, urgent care clinics, ICUs, nursing homes and assisted living facilities. With patents already approved in the United States, Europe and China, the company is positioned to dominate the market for portable brain imaging devices to address the current neurologist shortfall, improve patient outcomes and expand its vision for telemedicine in the neurology industry. For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Mobius Interactive Ltd. is strategically targeting global iGaming hotspots with three unique brands
• Club Double is targeting the emerging iGaming market in India
• Mobius.bet is expanding rapidly in the Brazilian market, as a top television sponsor for both the 2021/22 World Cup Qualifiers and for Italian Serie A football in August 2021
• Aragon Casino will target the regulated Canadian market

Mobius Interactive, a Vancouver-based online gaming company, has three distinct brands: Mobius.bet , Club Double and Aragon Casino. Paired with unique design and style, each brand targets specific geographical regions and demographics—offering a diverse and innovative iGaming experience to a wide range of players the world over. India is the fastest growing iGaming market in the world with an industry valued at $930m. Due to low-cost data, rising disposable incomes and the rollout of 5G, India was #1 in mobile downloads worldwide last year, downloading an astonishing 7.3 billion games. Club Double was created to tap into this emerging market, with the aura of old Hollywood and vintage Las Vegas in mind. This nostalgic brand aligns perfectly with the Bollywood genre, translating into early success for Mobius Interactive. Cricket is the most watched sport in India. Club Double is moving forward into the lucrative Indian market, with sports betting and a monthly calendar of events featuring daily cricket matches, not only inside of India, but all cricket games played around the world. Another national pastime is card games. For card players, Club Double provides the most popular live casino and casino games in the country. Aragon Casino brands itself along the lines of medieval and modern fantasy, echoing The Walking Dead and Game of Thrones. Aragon Casino, operating currently in Austria, Finland, the Balkans, Africa, and New Zealand, will move away from these regions and target the newly regulated Canadian market, beginning with Ontario. Mobius.bet is the flagship brand of Mobius Interactive, connecting players and a worldwide Esports community through loyalty programs and targeted gamification. Mobius.bet geographically focuses on Austria, Switzerland, Brazil, Latin America, and New Zealand. Mobius.bet will be launching into the Brazilian market on national TV with Serie A football starting 21 August 2021, followed by the 2021/22 FIFA World Cup Qualifiers. The soccer world is electric in Brazil: The Brazilian Olympic Team has just won back-to-back gold medals in soccer: a feat last accomplished by Argentina in 1908. The top World Cup qualifying match between the two greatest soccer rivals in the world, Brazil vs. Argentina, is expected to draw 40 million viewers on Globo TV Brazil.  Mobius Interactive is open for investment opportunities. For further information please contact: Gary Eldridge – President 1 (604) 783-1685   gary@mobiusinteractive.ltd  Seamus Byrne – VP Corporate Development 1 (902) 441-5757   seamus@mobiusinteractive.ltd For more information, visit the company’s website at www.MobiusInteractive.Ltd.  NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius